
|Videos|August 26, 2021
Part 2: IDH1 & IDH2 Inhibitors In Newly Diagnosed AML
Expert continues discussion of IDH1 and IDH2 inhibitors in AML and examines prioritization of IDH1 and IDH2 inhibitors versus venetoclax in newly diagnosed AML.
Advertisement
Episodes in this series

Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Current Pneumococcal Vaccination Recommendations: A Clinical Update
2
What Pharmacists Should Know About Most Favored Nation as Drug Prices Continue to Rise
3
Positive Phase 2a Trial Data Support FDA Clearance of StemCyte’s HPC Therapy for Long COVID
4
A Defining Moment for Health System Pharmacy: Advancing Competency, Policy, and Patient Need in 2026
5


























